Sanara MedTech Inc. Announces Second Quarter Earnings Release and Conference Call Dates
02 8월 2023 - 5:05AM
Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc.
(“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a
medical technology company focused on developing and
commercializing transformative technologies to improve clinical
outcomes and reduce healthcare expenditures in the surgical,
chronic wound and skincare markets, announced today details for the
release of its results for the quarter ended June 30, 2023.
Sanara will issue its earnings release on
Monday, August 14, 2023, and will host a conference call on
Tuesday, August 15, 2023, at 9:00 a.m. Eastern Time. The toll-free
number to call for this teleconference is 888-506-0062
(international callers: 973-528-0011) and the access code is
233776. A telephonic replay of the conference call will be
available through Tuesday, August 29, 2023, by dialing 877-481-4010
(international callers: 919-882-2331) and entering the replay
passcode: 48852.
A live webcast of Sanara’s conference call will
be available under the Investor Relations section of the Company's
website, www.SanaraMedTech.com. A one-year online replay will be
available after the conclusion of the live broadcast.
About Sanara
MedTech Inc.
With a focus on improving patient outcomes
through evidence-based healing solutions, Sanara MedTech Inc.
markets, distributes and develops surgical, wound and skincare
products for use by physicians and clinicians in hospitals, clinics
and all post-acute care settings and offers wound care and
dermatology virtual consultation services via telemedicine.
Sanara’s products are primarily sold in the North American advanced
wound care and surgical tissue repair markets. Sanara markets and
distributes CellerateRX® Surgical Activated Collagen®, FORTIFY TRG®
Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix as
well as a portfolio of advanced biologic products focusing on
AMPLIFY™ Verified Inductive Bone Matrix, ALLOCYTE® Advanced
Cellular Bone Matrix, BiFORM® Bioactive Moldable Matrix and
TEXAGEN® Amniotic Membrane Allograft to the surgical market. In
addition, the following products are sold in the wound care market:
BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS™
Antimicrobial Wound Gel, BIAKŌS® Antimicrobial Skin and Wound
Irrigation Solution and HYCOL® Hydrolyzed Collagen. Sanara’s
pipeline also contains potentially transformative product
candidates for mitigation of opportunistic pathogens and biofilm,
wound re-epithelialization and closure, necrotic tissue debridement
and cell compatible substrates. The Company believes it has the
ability to drive its pipeline from concept to preclinical and
clinical development while meeting quality and regulatory
requirements. Sanara is constantly seeking long-term strategic
partnerships with a focus on products that improve outcomes at a
lower overall cost. In addition, Sanara is actively seeking to
expand within its six focus areas of wound and skin care for the
acute, post-acute, and surgical markets. The focus areas are
debridement, biofilm removal, hydrolyzed collagen, advanced
biologics, negative pressure wound therapy products and the oxygen
delivery system segment of the wound and skincare markets.
Information about Forward-Looking
Statements
The statements in this press release that do not
constitute historical facts are “forward-looking statements,”
within the meaning of and subject to the safe harbor created by the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by terms such as “aim,” “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,”
“forecast,” “guidance,” “intend,” “may,” “plan,” “possible,”
“potential,” “predicts,” “preliminary,” “project,” “seek,”
“should,” “target,” “will,” or “would,” or the negatives of these
terms, variations of these terms or other similar expressions.
These forward-looking statements include, among others, statements
regarding our business strategy and mission, the development of new
products, the timing of commercialization of our products, the
regulatory approval process and expansion of the Company’s business
in telehealth and wound care. These items involve risks,
contingencies and uncertainties such as uncertainties associated
with the development and process for obtaining regulatory approval
for new products, the extent of product demand, market and customer
acceptance, the effect of economic conditions, competition,
pricing, the ability to consummate and integrate acquisitions, and
other risks, contingencies and uncertainties detailed in the
Company’s SEC filings, which could cause the Company’s actual
operating results, performance or business plans or prospects to
differ materially from those expressed in, or implied by these
statements.
All forward-looking statements speak only as of
the date on which they are made, and the Company undertakes no
obligation to revise any of these statements to reflect the future
circumstances or the occurrence of unanticipated events, except as
required by applicable securities laws.
Investor Contact:
Callon Nichols, Director of Investor
Relations713-826-0524CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.
Sanara MedTech (NASDAQ:SMTI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Sanara MedTech (NASDAQ:SMTI)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024